RE:RE:Bull ThesisAgree. Any listing announcement prior to signed partnerships (upfront capital hopefully), and other cataysts (dosage stuy completed), PH3 FDA start approval would be assine and likely further crater the stock. The company has sufficient cash on hand to proceed for now with PH3 (albiet not entire trial) and there is not a reason to rush listing without some or all of these mentioned catalysts.